Is leap Therapeutics a good stock to buy?

Leap Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. Leap Therapeutics has only been the subject of 2 research reports in the past 90 days. Read more about Leap Therapeutics' stock forecast and price target.

How does leap Therapeutics Inc (LPTx) stock compare to its peers?

Let’s briefly compare Leap Therapeutics Inc. (LPTX) stock to its peers. We find that current price change of 33.44% and -74.77% over the past 12 months for LPTX. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at 1.89% and 1.00%, respectively, at close of the trading.

What is the expected earnings of leap Therapeutics Inc (leap)?

Leap Therapeutics Inc. has a market cap of $53.41 million and is expected to release its quarterly earnings report on Mar 09, 2023 – Mar 13, 2023. Estimates by analysts give the company expected earnings per share (EPS) of -$0.12, with the EPS growth for the year raised at -$0.48 for 2022 and -$0.49 for next year.